Title: <scp>Glucagon‐like</scp> peptide‐1 receptor analogues in renal transplant recipients with diabetes: Medium term follow of patients from a single UK centre
Abstract: Diabetic MedicineVolume 40, Issue 5 e15057 LETTER Glucagon-like peptide-1 receptor analogues in renal transplant recipients with diabetes: Medium term follow of patients from a single UK centre Ritwika Mallik, Ritwika Mallik Department of Diabetes and Metabolism, The Royal London Hospital, London, UKSearch for more papers by this authorOmer Ali, Omer Ali Department of Nephrology, The Royal London Hospital, London, UKSearch for more papers by this authorMahalia Casabar, Mahalia Casabar Department of Nephrology, The Royal London Hospital, London, UKSearch for more papers by this authorDorcas Mukuba, Dorcas Mukuba Department of Diabetes and Metabolism, The Royal London Hospital, London, UKSearch for more papers by this authorConnor Byrne, Connor Byrne Department of Nephrology, The Royal London Hospital, London, UKSearch for more papers by this authorKieran McCafferty, Kieran McCafferty Department of Nephrology, The Royal London Hospital, London, UKSearch for more papers by this authorM. Magdi Yaqoob, M. Magdi Yaqoob Department of Nephrology, The Royal London Hospital, London, UKSearch for more papers by this authorTahseen A. Chowdhury, Corresponding Author Tahseen A. Chowdhury [email protected] orcid.org/0000-0001-8878-2331 Department of Diabetes and Metabolism, The Royal London Hospital, London, UK Correspondence Tahseen A. Chowdhury, 7th Floor, John Harrison House. The Royal London Hospital, Whitechapel, London E1 1BB, UK. Email: [email protected]Search for more papers by this author Ritwika Mallik, Ritwika Mallik Department of Diabetes and Metabolism, The Royal London Hospital, London, UKSearch for more papers by this authorOmer Ali, Omer Ali Department of Nephrology, The Royal London Hospital, London, UKSearch for more papers by this authorMahalia Casabar, Mahalia Casabar Department of Nephrology, The Royal London Hospital, London, UKSearch for more papers by this authorDorcas Mukuba, Dorcas Mukuba Department of Diabetes and Metabolism, The Royal London Hospital, London, UKSearch for more papers by this authorConnor Byrne, Connor Byrne Department of Nephrology, The Royal London Hospital, London, UKSearch for more papers by this authorKieran McCafferty, Kieran McCafferty Department of Nephrology, The Royal London Hospital, London, UKSearch for more papers by this authorM. Magdi Yaqoob, M. Magdi Yaqoob Department of Nephrology, The Royal London Hospital, London, UKSearch for more papers by this authorTahseen A. Chowdhury, Corresponding Author Tahseen A. Chowdhury [email protected] orcid.org/0000-0001-8878-2331 Department of Diabetes and Metabolism, The Royal London Hospital, London, UK Correspondence Tahseen A. Chowdhury, 7th Floor, John Harrison House. The Royal London Hospital, Whitechapel, London E1 1BB, UK. Email: [email protected]Search for more papers by this author First published: 31 January 2023 https://doi.org/10.1111/dme.15057Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Hagen M, Hagen M, Hjelmesæth J, Jenssen T, Mørkrid L, Hartmann A. A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant recipients. Nephrol Dial Transplant. 2003; 18(10): 2154-2159. 10.1093/ndt/gfg338 CASPubMedWeb of Science®Google Scholar 2Kuo HT, Sampaio MS, Vincenti F, Bunnapradist S. Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the organ procurement and transplant network/united network for organ sharing (OPTN/UNOS) database. Am J Kidney Dis. 2010; 56: 1127-1139. 10.1053/j.ajkd.2010.06.027 PubMedWeb of Science®Google Scholar 3Rodrigo E, Santos L, Piñera C, et al. Prediction at first year of incident new-onset diabetes after kidney transplantation by risk prediction models. Diabetes Care. 2012; 35: 471-473. 10.2337/dc11-2071 PubMedWeb of Science®Google Scholar 4Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394: 121-130. 10.1016/S0140-6736(19)31149-3 CASPubMedWeb of Science®Google Scholar 5Davies MJ, Bain SC, Atkin SL, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care. 2015; 39: 222-230. 10.2337/dc14-2883 PubMedWeb of Science®Google Scholar 6Øzbay LA, Smidt K, Mortensen DM, Carstens J, Jørgensen KA, Rungby J. Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1 E beta-cells. Br J Pharmacol. 2011; 162(1): 136-146. doi:10.1111/j.1476-5381.2010.01018.x 10.1111/j.1476-5381.2010.01018.x CASPubMedWeb of Science®Google Scholar 7Halden TA, Egeland EJ, Åsberg A, et al. GLP-1 restores altered insulin and glucagon secretion in Posttransplantation diabetes. Diabetes Care. 2016; 39(4): 617-624. doi:10.2337/dc15-2383 10.2337/dc15-2383 CASPubMedWeb of Science®Google Scholar 8Kukla A, Hill J, Merzkani M, et al. The use of GLP1R agonists for the treatment of type 2 diabetes in kidney transplant recipients. Transplant Direct. 2020; 6(2):e524. doi:10.1097/TXD.0000000000000971 10.1097/TXD.0000000000000971 CASPubMedWeb of Science®Google Scholar 9Thangavelu T, Lyden E, Shivaswamy V. A retrospective study of glucagon-like peptide 1 receptor agonists for the management of diabetes after transplantation. Diabetes Ther. 2020; 11(4): 987-994. doi:10.1007/s13300-020-00786-1 10.1007/s13300-020-00786-1 CASPubMedWeb of Science®Google Scholar 10Singh P, Pesavento TE, Washburn K, Walsh D, Meng S. Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients. Diabetes Obes Metab. 2019; 21(4): 1061-1065. doi:10.1111/dom.13619 10.1111/dom.13619 CASPubMedWeb of Science®Google Scholar Volume40, Issue5May 2023e15057 ReferencesRelatedInformation
Publication Year: 2023
Publication Date: 2023-02-01
Language: en
Type: letter
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot